Cannabis Law Report

AUGUST 19, 2021

Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Britain has experienced a “quiet cannabis revolution” that has transformed it into “the world’s second largest consumer cannabinoids market”, ACI said.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. & Notice of 2021 Final Results.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

NOVEMBER 12, 2021

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

MMJ Recs

JULY 30, 2024

Cannabis and PTSD: The Science Behind It Cannabis contains compounds called cannabinoids, which interact with the body’s endocannabinoid system (ECS). Research suggests that cannabinoids may modulate these processes, potentially offering relief from PTSD symptoms.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

MMJ Recs

JULY 9, 2024

In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients. ” Other cannabinoids, like cannabinol (CBN) and cannabigerol (CBG), also contribute to the plant’s medicinal benefits.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research. Investor Relations: Evan Veryard.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Del Morgan & Co.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

United Patients Group

JANUARY 8, 2023

This is because it contains cannabinoids, which have anti-inflammatory properties. Cannabinoids reduce inflammation in the body by limiting the amount of leukotrienes and prostaglandins that are released into your bloodstream when you’re injured, stressed or sick. Cannabis is anti-inflammatory.

Blood Pressure 122

Blood Pressure Sleep Cannabinoids Clinical Trials 122

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

SEPTEMBER 10, 2021

They have a strong pedigree in drug development which fits perfectly with the commercial and clinical expertise we have built within the Clerkenwell Health team”. Octarine Bio is a synthetic biology company based in Copenhagen, Denmark, which aims to deliver innovative cannabinoid and psychedelic treatments to improve health and wellbeing.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Clinical Trials.gov Identifier: NCT03787628 ).

Clinical Trials 40

Clinical Trials Treatment Research and Development Media 40

Cannabis Law Report

AUGUST 28, 2022

Cannabinoids are a class of chemical compounds found in the cannabis plant. There are over 100 cannabinoids, and they are responsible for the plant’s therapeutic effects. Cannabinoids interact with our body’s endocannabinoid system, which regulates many important functions, including mood, appetite, and pain.

Cannabinoids 52

Cannabinoids Trichome Treatment Clinical Trials 52

The Cannigma

MAY 6, 2021

Because most delta-8 products are derived from hemp plants, it is believed by some that they fall under a loophole in federal cannabis laws. Along with delta-9-THC, delta-8 is one of the few cannabinoids considered to be intoxicating. (El It is also touted as natural and safe. What is delta-8-THC. El Roi/123rf).

THC 145

THC Cannabinoids Concentrates Hemp 145

Veriheal

APRIL 11, 2022

federal law , it has not yet been used in any commonly prescribed medicines. The company initiated the first legal transfer (as deemed by federal law) to the U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based. federal law. Since cannabis is still a Schedule I substance under U.S.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 6, 2021

CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. Cannabinoids are the naturally occurring compounds found in the Cannabis plant. There are over 480 different Cannabinoids in the Cannabis plant. It is non-psychoactive and has a multitude of health benefits.

CBD 105

CBD Wellness and Beauty Treatment Pharmaceutical 105

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. Today there are 41 states that have enacted some form of a Right to Try or RTT laws. Cannabinoid Therapies for Cancer Patients.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

MARCH 7, 2023

Incannex Healthcare Limited, a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, announced that it has engaged Catalent (Catalent) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy (..)

Clinical Trials 52

Clinical Trials Therapy Pharmaceutical Medicine 52

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

CannaMD

NOVEMBER 15, 2020

research scene is also dominated by research on the harmful effects of cannabis, but Canada has dedicated much more funding to positive cannabinoid research. Non-profit organizations like the Canadian Consortium for Investigation of Cannabinoids (CCIC) were also formed to do research. Why isn’t more research done in the U.S.

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

Cannabis Law Report

DECEMBER 23, 2021

This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. C3 Cannabinoid Compound Company. However, no single cannabinoid drug has received widespread approval in the treatment of pain. However, regulations are constantly shifting.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

AUGUST 14, 2021

.” Meanwhile, Emyria has wasted no time in signing a deal with AltaSciences, under which the North American contract drug manufacturer will develop a range of synthetic cannabinoid-based capsules using Emyria’s EMD-003 over-the-counter program.

CBD 105

CBD Clinical Trials Programs Medicine 105

Cannabis Law Report

AUGUST 13, 2021

Instead, it is hypothesised that SalA indirectly influences the cannabinoid system, as well as being an allosteric modulator of the µ opioid receptor. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

CannaMD

AUGUST 8, 2020

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system. However, there are a number of restrictions.

CBD 105

CBD DEA Research and Development Hemp 105

Cannabis Law Report

MARCH 21, 2019

New laws and bills are constantly being passed that create a great deal of confusion in the cannabis world. All cannabis plants contain cannabinoids, which are a group of similar compounds. The industrial hemp plant happens to contain large quantities of special cannabinoids known as cannabidiol or CBD for short.

State Laws 55

State Laws Law CBD Legalization 55

Veriheal

JULY 7, 2023

Plants hit with HLVd show issues like yellow leaves, abnormal branching, stunted development, and nearly 50% loss in cannabinoid production. The new law covers the use of MDMA and psilocybin to treat certain conditions. Canada, and Israel are all conducting clinical trials on psychedelic treatments. Currently, the U.S.,

Legalization 97

Legalization Clinical Trials Research and Development History 97

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

The two active cannabinoids in marijuana are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which causes psychoactive effects while the former does not. This system naturally produces cannabinoids in the bloodstream, but chronic stress, anxiety, and other stimuli can stifle the production of natural endocannabinoids.

Treatment 111

Treatment Conditions CBD Clinical Trials 111